Biotech Stock News (AAVL) (AERI) (AGN) (KYTH) (RHHBY) (REGN) (PFE) (NVS)

Avalanche Biotech (NASDAQ:AAVL) Shares of Avalanche Biotech fell as much as 40% in after-hours trading on June 15, 2015 after the company announced results from its phase 2 wet-age related macular degeneration — wet-AMD — trial. The drop is huge but many investors should be assured that the drop was justified because the results were … Read more

Biotech Stock News (RXII)(REGN)(SNY)(ESPR)(ISIS)(BIIB)

Rxi Pharmaceuticals (NASDAQ:RXII) On June 9, 2015 shares of Rxi Pharmaceuticals went up 6% after the company reported that two new key patents were given to the company for use with their self-delivering sd-rxRNA technology platform. The new patents establish a few new details that enhance upon the company’s prospects: First the new patent is … Read more

Biotech Stock News (AZN) (AMGN) (NVS) (LLY) (HRTX) (MRK)

AstraZeneca (NYSE:AZN) & Amgen (NASDAQ:AMGN) On May 26, 2015 both AstraZeneca and Amgen announced that it would end a partnership established back in 2012 for a psoriasis drug collaboration. This collaboration established in 2012 allowed Astrazeneca to work on five antibody compounds from Amgen’s anti-inflammation drug pipeline. Amgen received an upfront payment of at least … Read more

Biotech Stock News (SRPT) (BMRN) (PBMD) (ISR)

Sarepta Therapeutics (NASDAQ:SRPT) After the closing bell on May 19, 2015 shares of Sarepta Therapeutics were up as much as 38% in after-hours trading after the company reported that the FDA will allow the company to file a New Drug Application — NDA — for Eteplirsen. This drug Eteplirsen helps patients with Duchenne Muscular Dystrophy … Read more

Biotech Stock News (OREX) (TKPHF) (VRTX) (PBYI)

Orexigen Therapeutics (NASDAQ:OREX)  On May 12, 2015 Shares of Orexigen tanked by 13% after the company reported that the cardiovascular outcome study had to be terminated early. The “LIGHT” study recruited up to 9,000 patients to determine if patients taking Contrave have an increased risk of cardiovascular issues. The mess up occurred because the early … Read more

Biotech Stock News (CLDN) (BLUE) (QURE) (ONCE) (CANF) (AMGN) (MRK) (BMY)

Celladon Corporation (NASDAQ:CLDN) On April 26, 2015 Shares of Celladon Corporation tumbled 80% in one day after the company reported that its phase 2 trial using Mydicar to treat heart failure patients failed to meet on both the primary endpoint and the secondary endpoint. The phase 2 trial was known as CUPID-2 and recruited up … Read more

Amarin (AMRN) Stock Falls As FDA CRL Is Announced

Amarin Corporation plc (ADR) (NASDAQ: AMRN) A couple of months ago, we talked about how Amarin’s diet pill Vascepa possibly had heart health benefits. If you remember, the FDA was very clear about the fact that Amarin shouldn’t have announced that they have found their drug to provide heart benefits until approval was provided. Today, … Read more

Biotech Stock News (AMPE) (ALNY) (AERI)

Ampio Pharmaceuticals (NASDAQ:AMPE) On April 20, 2015 Shares of Ampio Pharmaceuticals fell about 66% after the company reported that it had failed to meet the primary endpoint of a phase 3 clinical trial, known as the STRIDE trial. This trial recruited 320 patients with Osteoarthritis and patients were randomized into two different groups. One group … Read more

Biotech Stock News (ARWR)(AMGN)(ATHX)(PFE)

Arrowhead Research Corp (NASDAQ:ARWR) On April 13, 2015 Arrowhead announced that it was given the go-ahead by the FDA to begin treating patients in the phase 2b Hepatitis B study.  The drug compound being used in the study is known as ARC-520 which is an RNAi drug. RNAi stands for RNA interference and these types … Read more

Biotech Stock News (RGLS)(AZN)(INO)(TKMR)

Regulus Therapeutics (NASDAQ:RGLS) & AstraZeneca (NYSE:AZN)  On April 7, 2015 Shares of Regulus were up about 8% in after hours trading after the company reported that Astrazeneca would like to collaborate with the company to develop a NASH drug. NASH stands for non-alcoholic steatohepatitis and as the name suggests it is a disease that doesn’t … Read more